Matthew Stritt, MD
Internal Medicine · Hastings, NENPI 1578720058
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Johnson & Johnson at 33.2% of the total. Reporting peaked in 2024 at $2,077 and has fallen 75.7% since, to $504 in 2025. Among internal medicine clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $41.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Medical Device Business Services, Inc.$2K
- AstraZeneca$564
- GSK$416
- United Therapeutics Corporation$138
- Amgen$120
- plus $986 from 23 others
What the payments were for
- Travel & lodging$2,91252%
- Food & beverage$2,72848%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 10 | $1,872 |
| Medical Device Business Services, Inc. | 7 | $1,549 |
| AstraZeneca | 21 | $564 |
| GSK | 34 | $416 |
| United Therapeutics Corporation | 4 | $138 |
| Amgen | 6 | $120 |
| Boehringer Ingelheim | 7 | $115 |
| Grifols USA, LLC | 6 | $109 |
| Insmed, Inc. | 5 | $90 |
| Inspire Medical Systems, Inc. | 3 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
| Sanofi | 3 | $57 |
| Mylan Specialty L.p. | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 3 | $54 |
| Harmony Biosciences LLC | 3 | $42 |
| Verona Pharma, Inc. | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $30 |
| Pfizer | 1 | $28 |
| Merck | 1 | $26 |
| Philips North America LLC | 2 | $25 |
| Viatris Specialty LLC | 1 | $24 |
| Olympus America Inc. | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Baxter Healthcare | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Ceribell, Inc. | 1 | $16 |
| Pulmonx Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$1,773
- MONARCH$1,491
- SYMBICORT$124
- FASENRA$124
How this compares
$5,646 in reported general payments places this provider in the 90th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 64 | $836,791 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 784 | $560,211 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 211 | $159,273 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 227 | $108,400 |
| Breo ElliptaFluticasone/Vilanterol | 229 | $94,494 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 44 | $20,926 |
| Spiriva RespimatTiotropium Bromide | 34 | $17,451 |
| Incruse ElliptaUmeclidinium Bromide | 39 | $16,674 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $9,691 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 79 | $9,098 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 266 | $8,696 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 18 | $7,681 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 37 | $7,530 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,669 |
| Ventolin HfaAlbuterol Sulfate | 53 | $3,617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $115 | $875,169142 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $416 | $779,7791,279 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $564 | $176,644268 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Hastings
- Justin WenburgHastings$10K
- Paul WibbelsHastings$9K
- Douglas HentzenHastings$9K
- Michelle SeizysHastings$5K
- Richard FrenchHastings$4K
- Brian BoerOmaha$142K
- Sherri ThomasLincoln$136K
- Adam BurdorfOmaha$29K
- David SharpOmaha$26K
- David ShinOmaha$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.